Analysis reveals that inflammatory markers do not effectively distinguish pathologies in low-risk prostate patients, suggesting limits for early detection methods.
Hematological inflammatory parameters before prostate biopsy are not effective markers for distinguishing between biopsy negative and malignant pathologies. The inflammatory markers SII and PLR can be used as diagnostic tools in high-risk prostate cancer patients but cannot be used as markers for the detection of pathologies in low- and intermediate-risk patients.
No takes yet. Share an insight, caveat, or question.
Kaçan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: